Will Medicare Cover Weight-Loss Drugs in 2026? What New Obesity Medications Mean for Access, Costs, and Care

Why This Question Matters in 2026

Interest in prescription weight-loss drugs has surged across the United States. Medications such as semaglutide (Wegovy) and tirzepatide (Zepbound) have shown substantial weight loss in large clinical trials. At the same time, their list prices can reach well over $1,000 per month without insurance coverage.

For adults over 65 and people with disabilities who rely on Medicare, one key question remains: Will Medicare cover these drugs for obesity in 2026?

The short answer is that Medicare’s coverage is shaped by federal law, not just medical evidence. While these medications are FDA-approved for chronic weight management, Medicare Part D has historically excluded drugs used solely for weight loss. Understanding that distinction is essential before starting treatment.

Obesity Is a Medical Condition — Not Just a Lifestyle Issue

Obesity is defined medically, usually by body mass index (BMI). In adults:

BMI 30 or higher is classified as obesity.
BMI 25–29.9 is considered overweight.

According to the Centers for Disease Control and Prevention (CDC), more than 40% of U.S. adults meet criteria for obesity. Rates are also high among older adults, which means Medicare beneficiaries are directly affected.

The U.S. Preventive Services Task Force (USPSTF) recommends screening all adults for obesity and offering or referring those with obesity to intensive, multicomponent behavioral interventions. That recommendation recognizes obesity as a chronic disease that increases risk for type 2 diabetes, heart disease, stroke, certain cancers, and other conditions.

Behavioral programs—nutrition counseling, physical activity support, and behavioral therapy—remain the foundation of treatment. Medications are generally considered when those measures alone are not enough.

What the Newer Medications Actually Do

Two of the most discussed medications are:

Wegovy (semaglutide)
Zepbound (tirzepatide)

According to the U.S. Food and Drug Administration (FDA), both are approved for chronic weight management in adults with:

BMI of 30 or higher, or
BMI of 27 or higher with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

These medications work by mimicking gut hormones that regulate appetite and fullness. Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GIP and GLP-1 receptors. They help people feel full sooner and reduce overall calorie intake.

What the Clinical Trials Showed

The evidence behind these drugs comes from large randomized controlled trials (RCTs):

The STEP trials studied semaglutide in adults with overweight or obesity. Participants lost an average of about 15% of their body weight over roughly 68 weeks when combined with lifestyle changes.
The SURMOUNT trials studied tirzepatide and reported average weight loss approaching 20% or more at higher doses over about 72 weeks.

These were high-quality RCTs involving thousands of participants. However, important limitations apply:

They required ongoing injections; weight regain often occurred when medication was stopped.
Participants received structured lifestyle support, which may not reflect real-world access.
Long-term outcomes beyond several years are still being studied.

Common side effects include nausea, vomiting, diarrhea, and constipation. The FDA also notes warnings about rare but serious risks, such as pancreatitis and certain thyroid tumors in animal studies. These medications are not appropriate for everyone.

They are tools for chronic disease management—not cures.

What Medicare Covers — and What It Doesn’t

Medicare drug coverage is provided through Part D plans and Medicare Advantage plans with drug benefits. Under federal law, Medicare Part D has historically excluded drugs used “for anorexia, weight loss, or weight gain.” The Centers for Medicare & Medicaid Services (CMS) outlines these statutory exclusions in its Part D guidance.

That means that when a medication is prescribed solely for weight loss, traditional Part D plans generally do not cover it.

This exclusion is not a clinical decision—it is written into statute. Changing it would require federal legislative action.

When Coverage May Apply

There are important exceptions that can affect access in 2026.

1. If the Drug Is Prescribed for Another FDA-Approved Indication

Some medications in the same class are approved for type 2 diabetes. For example, semaglutide is also marketed under a different brand for diabetes treatment. Diabetes medications are covered under Part D.

If a beneficiary has type 2 diabetes and the drug is prescribed for that condition, coverage may apply under diabetes benefits—not as a weight-loss drug.

2. Cardiovascular Risk Reduction Indications

The FDA has expanded certain labels to include reduction of cardiovascular risk in specific high-risk populations. When a drug is prescribed for a covered indication such as established cardiovascular disease, Part D coverage may be allowed, depending on the plan’s formulary rules.

However, approval does not automatically guarantee coverage. Plans may require prior authorization or step therapy.

3. Medicare Advantage Plan Differences

Some Medicare Advantage plans may structure formularies differently, but they must still follow federal law regarding excluded drug categories.

4. Medicaid Variation by State

Unlike Medicare, Medicaid drug coverage decisions vary by state. Some state Medicaid programs have begun covering certain obesity medications under specific criteria, while others have not. Eligibility, prior authorization rules, and cost-sharing differ widely.

Costs and Access in the Real World

Without insurance coverage, monthly list prices for these medications can exceed $1,000. Actual out-of-pocket costs depend on:

Whether the drug is covered under a qualifying indication
Plan formulary placement
Deductibles and coinsurance
Whether the patient qualifies for manufacturer assistance programs (which typically do not apply to Medicare beneficiaries due to federal anti-kickback rules)

Even when covered, many plans require prior authorization. Patients may need documentation of BMI, weight-related conditions, and prior attempts at lifestyle therapy.

Access raises equity concerns. Obesity rates are high among lower-income adults and communities of color. If medications remain largely uncovered under Medicare, cost becomes a major barrier for older adults living on fixed incomes.

What This Means for Patients and Families

If you or a family member is considering a weight-loss medication in 2026:

Check your specific Part D or Medicare Advantage plan formulary.
Ask whether the drug is covered for your diagnosis.
Clarify prior authorization requirements.
Discuss alternative covered treatments with your clinician.
Review behavioral therapy options recommended by the USPSTF.

Obesity is recognized as a chronic disease, and effective prescription treatments now exist. But insurance coverage decisions are shaped by federal policy as much as by medical evidence.

Before starting therapy, patients should understand not only potential benefits and side effects—but also long-term cost and coverage realities.

Bottom Line

In 2026, Medicare generally does not cover medications prescribed solely for weight loss because of a long-standing statutory exclusion under Part D. Coverage may apply when these drugs are prescribed for other FDA-approved conditions such as type 2 diabetes or certain cardiovascular indications.

The science has advanced. Policy is still catching up. For now, careful review of your individual coverage—and an open conversation with your healthcare provider—remains the most practical next step.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.